ALZAMEND NEURO, INC. Cash
ALZAMEND NEURO, INC. (ALZN) had Cash of $7.60 million as of 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:Cash · last filed 2026-09-10
- 2026-07-31: Cash $7.60M.
- 2026-04-30: Cash $711.00K.
- 2026-01-31: Cash $2.70M.
- 2025-10-31: Cash $4.40M.
| Period end | Cash |
|---|---|
| 2026-07-31 | $7.60M 10-Q · filed 2026-09-10 |
| 2026-04-30 | $711.00K 10-K · filed 2026-07-22 |
| 2026-01-31 | $2.70M 10-Q · filed 2026-03-11 |
| 2025-10-31 | $4.40M 10-Q · filed 2025-12-09 |
| 2025-07-31 | $5.60M 10-Q · filed 2025-09-10 |
| 2025-04-30 | $3.90M 10-K · filed 2026-07-22 |
| 2025-01-31 | $3.40M 10-Q · filed 2025-03-10 |
| 2024-10-31 | $4.10M 10-Q · filed 2024-12-11 |
| 2024-07-31 | $1.20M 10-Q · filed 2024-09-11 |
| 2024-04-30 | $376.00K 10-K · filed 2025-07-22 |
| 2024-01-31 | $283.00K 10-Q · filed 2024-03-25 |
| 2023-07-31 | $1.70M 10-Q · filed 2023-09-13 |
| 2023-04-30 | $5.10M 10-K · filed 2024-07-30 |
| 2023-01-31 | $7.40M 10-Q · filed 2023-03-15 |
| 2022-10-31 | $9.20M 10-Q · filed 2022-12-12 |
| 2022-07-31 | $11.50M 10-Q · filed 2022-09-13 |
| 2022-04-30 | $14.10M 10-K · filed 2023-07-27 |
| 2022-01-31 | $11.80M 10-Q · filed 2022-03-15 |
| 2021-10-31 | $13.60M 10-Q · filed 2021-12-13 |
| 2021-07-31 | $15.60M 10-Q · filed 2021-09-13 |
| 2021-04-30 | $1.90M 10-K · filed 2022-07-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |